US EditionPublished • loading... • Updated
Malaria: Ganaplacid in Phase 3 Trial Similarly Effective to Artemisinin
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Washington – In a Phase 3 trial, the novel drug ganaplacid, in oral combination with lumefantrine, cured uncomplicated malaria after three days of treatment as effectively as the current standard of artemisinin-based therapy. The effectiveness of the latter is threatened by the increasing resistance of Plasmodium falciparum...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
